 Today, I have the pleasure of speaking with Steve Saviek from Vallejo Pharma. How are you today? Very good, Tracy. It's nice to be back on Investor Channel. You've had so much news this week, but let's start with the big one, the money. $40 million in non-dilutive financing from Segar health care partners. Let's start there. Give us an update on this, please. We signed and concluded a transaction with Segar on Friday afternoon. Segar is a major life science fund in Canada, very knowledgeable. The financing is for a total of US$40 million, which we've drawn down 30 million, and that 30 million is earmarked to support the acquisition of several products, which we'll talk about later, as well as for working capital. There's a further 10 million to bring it up to 40, which is on the table for future acquisitions. Clearly, this is a financing that helps us now, but also helps us in the future. Of course, the additional 10 million, I know the timeline is December 2023, so they have quite a clip happening for you to achieve these milestones. We're very active on the business development front. The fact that we open up this new therapeutic area with one of our acquisitions in ophthalmology, there's a lot going on in ophthalmology that excites us, the two products that we licensed in that we'll talk about later, but also others that potentially could be in the pipeline. It's a very interesting dynamic right now in the pharma space. There's a lot of divestiture going on by the major companies, the multinationals, and that bodes well for companies such as Valeo. Of course, I think during allergy season, this is timely, but can you tell me why they selected Valeo for this $40 million financing? I'm assuming your infrastructure is in place, you've been building quite a sales team here over the last year. I think we've got a fairly unique or certainly rare positioning in Canada as a Canadian-centric pharmaceutical company. Our asthma assets that we've talked about in prior visits, Enterzair and Atuk Tura are doing very well, and that certainly caught their attention as these assets will grow in revenues to what we estimate to be well over $100 million. In addition, Cigar was very familiar with the or at least had some familiarity with the products that we were seeking to acquire in this round, and I think they like those products. They saw the synergistic fit with Valeo. I think it's a lot of things that came together. We're saying it's just the right place, the right time with the right products, and again, a partner that we couldn't be happier to welcome on board. For those of you unfamiliar with Cigar Healthcare, perhaps they know a little bit more about you, Steve, because of your professional experience, or did you just meet them during your time at Valeo? No, it was actually through an intermediary that we were introduced to Cigar. We were looking for a partner, a financial partner to support our growth, and they came up to the top of the list. We got on very well with them. I believe they thought highly of our management team. They like our existing products, particularly our two asthma therapies that have tremendous potential, and then they had some familiarity with the products we were going to acquire through these transactions. I think that it all came together as the right place, the right time with the right products. Of course, you put two other news releases out the same day. How are they tied into this financing? The three are three parts of the puzzle. The Cigar money was there to fund these two new press releases, to fund the assets we acquired under them, and the assets we acquired needed financing. They needed financing for upfront milestone payments for working capital build, which is quite significant. It was the hand-fitting the glove. The three came together as one. So the financing happened, and then you announced your license agreement with Kaleo for the Canadian rights to Allerject. Is that correct? Correct. So Kaleo is a U.S.-based company. Allerject is a very innovative, and I'll actually show it to you here. It's rare that you can actually show something that viewers can see. This is what Allerject looks like. It's an epinephrine injector. For those people that suffer from severe allergies, where they need to inject themselves, should they take whatever the peanuts or shellfish or what have you, the existing product on the market that really has a majority of the market share is EpiPen. This product has been launched in the U.S., doing very well there. It had been launched in Canada, and we're relaunching it. Sales were $4 million last year. We expect sales to grow to about $25 million. Innovative, speaks to you, very small, and very safe. So of course, for all of you out there with allergies, in addition to the epinephrine auto injectors, you also made an agreement with an ophthalmic product for eyes, dry eyes, basically. Is that correct? So this is a licensing agreement we entered into with Novartis. So this is our second major agreement with Novartis. As you can recall, our first was for the two asthma therapies. Two products, Zidra, which is a prescription dry eye medication, and Symbrynsa, which is a prescription solution for glaucoma, which is high blood pressure in the eye. Both interesting products, both patented. Both work well together in terms of being promoted to physicians together. A lot of synergies with these two products together. Very excited, and it sets us up in a new therapeutic area, ophthalmology, which we believe with these two products. We've had combined sales last year of approximately $24 million. So that's going to significant bump to our top line, but also with the potential to grow significantly and also attract other ophthalmology assets over time. Lots of good news here. We know you're intensely busy. I'm not even going to ask you what's going to happen next. All I want to say is congratulations on the significant news. And is there anything else you'd like to add that you would like to point out to people about all of this news, that significant news that has just come out here in the last week? Well, I would say the financing secures us going forward in a non-diluted way. That's very important. I think a lot of people wanted to know that where would we get the money to grow the business? As you can see, the SEGARD financing provides that. The three products we just announced, more than double our current revenue run rate. So we're becoming a pretty significant player now in Canada, which was our aspirations. And I could just see that growth continuing. All of our major products, we have a total product count now of 11, but six of which I would say are our major marketed brands, all have revenue growth potential. So very exciting times for Valeo and for our shareholders also. Steve, as always, thank you for joining us. And we look forward to getting this out to the investor intel audience as quickly as possible. And for more information, go to Valeo Pharma's website. Thank you, Steve. Thanks. It's very much Tracy.